Lexicon Pharmaceuticals (LXRX) stock price, revenue, and financials

Lexicon Pharmaceuticals market cap is $762.3 m, and annual revenue was $322.07 m in FY 2019

$762.3 M

LXRX Mkt cap, 12-Nov-2021

$27 K

Lexicon Pharmaceuticals Revenue Q1, 2021
Lexicon Pharmaceuticals Gross profit (Q1, 2021)27 K
Lexicon Pharmaceuticals Gross profit margin (Q1, 2021), %100%
Lexicon Pharmaceuticals Net income (Q1, 2021)-21 M
Lexicon Pharmaceuticals EBIT (Q1, 2021)-20.8 M
Lexicon Pharmaceuticals Cash, 31-Mar-202197.7 M
Lexicon Pharmaceuticals EV676.4 M
Get notified regarding key financial metrics and revenue changes at Lexicon PharmaceuticalsLearn more
Banner background

Lexicon Pharmaceuticals Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.8m1.1m2.2m22.9m130.0m83.3m90.3m63.2m322.1m

Revenue growth, %

929%469%(36%)

Cost of goods sold

1.9m2.5m3.2m

Gross profit

88.4m60.7m318.8m

Gross profit Margin, %

98%96%99%

R&D expense

91.8m82.6m89.7m89.3m95.2m156.8m100.2m91.9m

General and administrative expense

17.4m17.0m17.1m19.4m23.8m66.2m63.8m56.8m

Operating expense total

109.2m99.6m106.8m108.7m119.0m225.1m164.0m177.4m

EBIT

(114.1m)(108.4m)(102.4m)(100.4m)1.5m(137.2m)(136.7m)(103.3m)141.4m

EBIT margin, %

(6171%)(9955%)(4607%)(439%)1%(165%)(151%)(163%)44%

Interest expense

2.5m2.1m2.0m2.3m6.6m

Interest income

255.0k213.0k157.0k2.3m

Pre tax profit

(116.2m)(110.2m)(100.4m)(4.7m)(141.4m)(141.7m)(120.5m)124.1m

Income tax expense

(70.0k)(12.7m)(6.0m)

Net Income

(116.2m)(110.2m)(104.1m)(100.3m)(4.7m)(141.4m)(129.0m)(120.5m)130.1m

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021

Revenue

555.0k355.0k300.0k199.0k372.0k360.0k214.0k238.0k277.0k676.0k419.0k1.8m376.0k566.0k12.5m20.1m27.7m18.3m12.1m26.9m25.2m13.8m6.9m9.2m9.7m294.4m8.0m6.6m27.0k

Cost of goods sold

225.0k537.0k599.0k533.0k838.0k551.0k553.0k1.3m577.0k568.0k633.0k

Gross profit

18.1m11.5m26.3m24.7m12.9m6.3m8.7m8.4m293.9m7.4m6.0m27.0k

Gross profit Margin, %

99%96%98%98%94%92%94%86%100%93%90%100%

R&D expense

20.1m19.7m23.0m19.4m19.2m20.3m23.7m25.4m24.0m21.2m24.1m20.9m20.8m23.1m37.0m48.2m52.5m43.6m26.9m39.1m47.8m26.6m13.8m12.0m12.6m26.7m55.2m40.1m12.6m

General and administrative expense

4.5m4.1m4.6m4.2m4.4m4.3m4.7m4.7m5.7m5.2m4.6m5.7m6.3m5.4m8.4m8.4m12.3m14.9m18.5m16.7m14.9m

Operating expense total

24.7m23.7m27.6m23.5m23.6m24.7m28.4m30.1m29.6m26.3m28.7m26.6m27.1m28.5m45.4m56.6m64.8m60.6m45.4m55.9m62.6m43.3m29.3m26.1m26.9m69.2m69.9m(80.7m)20.9m

EBIT

(25.9m)(25.7m)(29.4m)(25.5m)(29.1m)(25.6m)(28.6m)(31.2m)(30.5m)(26.1m)(40.3m)(26.5m)(26.7m)(33.7m)(33.9m)(37.0m)(34.9m)(42.5m)(33.9m)(29.5m)(38.0m)(30.4m)(23.0m)(17.5m)(18.5m)224.7m(62.4m)86.7m(20.8m)

EBIT margin, %

(4671%)(7237%)(9794%)(12804%)(7812%)(7099%)(13376%)(13116%)(11001%)(3863%)(9627%)(1480%)(7098%)(5950%)(271%)(184%)(126%)(232%)(281%)(110%)(151%)(221%)(336%)(190%)(192%)76%(781%)1307%(77181%)

Interest expense

810.0k560.0k537.0k530.0k527.0k506.0k496.0k492.0k457.0k455.0k449.0k1.7m

Interest income

68.0k60.0k56.0k58.0k44.0k53.0k44.0k39.0k8.0k4.0k5.0k

Pre tax profit

(26.1m)(43.5m)(35.1m)(30.7m)(42.1m)(34.7m)(27.5m)220.1m82.6m

Income tax expense

(8.7m)

Net Income

(26.6m)(26.1m)(29.9m)(25.9m)(29.5m)(26.0m)(29.1m)(31.7m)(30.8m)(26.0m)(40.5m)(28.1m)(28.1m)(35.3m)(34.9m)(38.1m)(36.0m)(34.9m)(35.1m)(30.7m)(42.1m)(34.7m)(27.5m)(21.8m)(23.0m)226.1m(66.6m)82.6m(21.0m)

Lexicon Pharmaceuticals Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021

Cash

20.3m30.5m29.0m33.8m20.8m34.2m23.3m19.6m46.5m27.7m26.8m42.0m9.7m61.7m24.7m38.4m38.8m2.5m30.7m83.3m20.4m15.0m48.9m45.8m11.1m170.2m55.6m52.3m97.7m

Accounts Receivable

505.0k489.0k186.0k182.0k233.0k863.0k1.0m895.0k471.0k281.0k165.0k170.0k316.0k72.0k741.0k1.0m738.0k8.7m5.0m10.6m4.5m4.4m2.9m4.4m5.6m56.8m30.1m1.4m101.0k

Prepaid Expenses

3.9m4.3m5.1m6.6m9.0m8.4m6.7m7.3m6.6m7.3m5.9m3.2m7.2m11.0m14.3m9.1m2.4m10.4m10.2m4.5m4.3m4.0m3.4m4.7m6.6m6.0m

Inventories

236.0k811.0k2.1m2.1m2.1m4.8m4.6m4.3m4.5m4.1m

Current Assets

169.2m149.0m259.0m238.3m216.1m206.5m183.1m159.4m105.4m86.7m87.8m342.3m313.8m288.9m492.2m439.5m398.7m279.1m247.2m214.0m273.2m220.2m198.4m146.8m122.5m363.6m291.6m121.9m145.4m

PP&E

48.4m47.3m45.5m44.5m43.5m42.6m42.2m41.8m40.0m39.2m1.5m732.0k684.0k795.0k20.8m20.4m19.9m19.0m18.6m18.2m17.2m16.8m16.3m15.5m15.0m14.5m13.6m11.1m296.0k

Goodwill

44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m44.5m

Total Assets

315.9m294.7m402.8m381.1m357.8m347.3m323.4m299.5m243.6m224.1m187.5m444.7m416.0m391.1m611.3m558.1m516.9m396.3m363.5m329.5m386.8m332.9m310.2m258.5m233.1m444.6m370.6m178.9m193.3m

Accounts Payable

3.7m5.5m5.3m4.6m4.3m5.4m6.3m9.7m7.1m8.4m9.7m12.1m11.3m16.4m25.5m28.2m41.5m41.9m43.9m52.6m66.6m50.5m51.5m13.9m10.0m20.9m18.2m11.7m4.9m

Short-term debt

1.4m1.4m1.5m1.5m1.5m1.6m22.7m1.7m1.7m1.8m20.6m19.7m19.3m18.8m2.0m17.3m16.8m15.8m15.2m14.6m13.5m12.9m1.1m1.1m1.1m11.3m10.7m8.7m11.7m

Current Liabilities

13.2m14.8m20.9m21.6m19.1m17.4m40.9m23.6m17.7m21.9m44.3m45.9m43.6m51.8m121.9m131.0m170.1m137.1m133.2m128.7m100.4m81.3m68.5m28.2m22.5m44.8m80.3m78.9m39.0m

Long-term debt

24.2m23.8m23.1m22.7m22.3m21.5m20.6m19.7m19.3m87.5m87.5m87.5m100.6m84.9m85.0m85.3m85.4m85.5m231.9m232.2m243.8m243.9m244.0m235.1m234.5m11.6m

Total Debt

25.6m25.2m24.5m24.2m23.8m23.1m22.7m22.3m21.5m21.0m20.6m107.2m106.8m106.3m102.6m102.2m101.8m101.0m100.5m100.1m245.4m245.1m244.9m246.5m246.4m246.3m245.2m20.3m11.7m

Total Liabilities

121.7m125.2m133.8m136.2m105.1m105.1m108.3m113.7m102.8m107.4m109.7m187.1m184.5m193.2m358.5m340.8m331.8m261.7m257.2m251.1m360.6m338.0m339.6m304.2m298.0m279.9m315.8m91.3m40.7m

Common Stock

338.0k338.0k481.0k481.0k495.0k514.0k514.0k514.0k516.0k516.0k516.0k727.0k104.0k104.0k104.0k104.0k104.0k105.0k105.0k106.0k106.0k106.0k106.0k106.0k106.0k106.0k108.0k117.0k145.0k

Additional Paid-in Capital

923.8m925.2m1.1b1.1b1.1b1.2b1.2b1.2b1.2b1.2b1.2b1.4b1.4b1.4b1.4b1.4b1.4b1.4b1.4b1.4b1.4b1.4b1.4b1.5b1.5b1.5b1.5b1.5b1.6b

Retained Earnings

(729.7m)(755.8m)(819.5m)(845.4m)(875.0m)(925.8m)(954.9m)(986.5m)(1.0b)(1.1b)(1.1b)(1.1b)(1.2b)(1.2b)(1.1b)(1.2b)(1.2b)(1.3b)(1.3b)(1.4b)(1.4b)(1.4b)(1.5b)(1.5b)(1.5b)(1.3b)(1.4b)(1.4b)(1.4b)

Total Equity

194.2m169.5m269.0m244.9m252.8m242.2m215.1m185.7m140.8m116.7m77.8m257.6m231.5m197.9m252.9m217.3m185.2m134.6m106.3m78.4m26.2m(5.1m)(29.4m)(45.7m)(64.9m)164.7m54.8m87.6m152.5m

Debt to Equity Ratio

0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.2 x0.2 x0.3 x0.4 x0.5 x0.5 x0.4 x0.5 x0.5 x0.8 x0.9 x1.3 x9.4 x-48.3 x-8.3 x-5.4 x-3.8 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.2 x0.3 x0.3 x0.2 x0.2 x0.2 x0.3 x0.3 x0.3 x0.6 x0.7 x0.8 x1 x1.1 x

Financial Leverage

1.6 x1.7 x1.5 x1.6 x1.4 x1.4 x1.5 x1.6 x1.7 x1.9 x2.4 x1.7 x1.8 x2 x2.4 x2.6 x2.8 x2.9 x3.4 x4.2 x14.8 x-65.7 x-10.6 x-5.7 x-3.6 x2.7 x6.8 x2 x1.3 x

Lexicon Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021

Net Income

(56.3m)(82.4m)(29.9m)(55.8m)(85.3m)(26.0m)(55.1m)(86.7m)(30.8m)(56.9m)(97.4m)(28.1m)(56.1m)(91.4m)(34.9m)(73.0m)(109.0m)(34.9m)(69.9m)(100.7m)(42.1m)(76.8m)(104.3m)(21.8m)(44.8m)181.3m(66.6m)(53.1m)(21.0m)

Depreciation and Amortization

2.6m3.8m1.1m2.2m3.3m793.0k1.6m2.2m644.0k1.2m1.7m355.0k601.0k661.0k521.0k1.0m1.5m634.0k1.6m2.5m925.0k1.9m2.8m901.0k1.8m2.7m906.0k2.6m37.0k

Accounts Receivable

239.0k255.0k164.0k168.0k117.0k515.0k364.0k483.0k319.0k509.0k625.0k865.0k719.0k963.0k170.0k(107.0k)173.0k(1.2m)2.5m(3.1m)343.0k419.0k1.9m1.5m344.0k(50.9m)26.4m52.2m294.0k

Inventories

(236.0k)(811.0k)(2.1m)(164.0k)(194.0k)(2.8m)74.0k403.0k204.0k96.0k345.0k

Accounts Payable

(2.4m)(3.8m)851.0k317.0k1.9m905.0k(2.3m)(11.7m)9.5m(6.6m)(4.7m)(8.2m)(13.8m)(645.0k)15.1m14.3m(8.4m)

Cash From Operating Activities

(45.2m)(65.4m)(27.0m)(49.0m)(74.0m)(24.3m)(45.4m)(69.3m)(30.3m)(50.0m)(71.2m)(23.5m)(55.7m)(81.1m)(43.7m)(91.6m)(126.8m)(85.5m)(117.7m)(151.7m)(46.8m)(99.3m)(121.5m)(25.6m)(52.5m)138.2m(22.1m)(108.7m)(25.2m)

Purchases of PP&E

(815.0k)(997.0k)(234.0k)(329.0k)(379.0k)(839.0k)(1.2m)(1.5m)(28.0k)(39.0k)(46.0k)(17.0k)(480.0k)(664.0k)(54.0k)(67.0k)(83.0k)(92.0k)(163.0k)(224.0k)(40.0k)(55.0k)(58.0k)(70.0k)(70.0k)(70.0k)(33.0k)(38.0k)

Cash From Investing Activities

21.2m51.9m(129.6m)(102.7m)(91.1m)29.1m39.5m59.8m40.6m41.8m62.3m(71.0m)(70.7m)7.1m(133.6m)(72.1m)(38.2m)42.5m99.2m186.3m7.1m54.4m110.8m(7.7m)(15.2m)(46.5m)42.8m336.7m(17.7m)

Long-term Borrowings

(2.9m)(3.2m)(353.0k)(706.0k)(1.1m)(387.0k)(773.0k)(1.2m)(420.0k)(839.0k)(1.3m)(456.0k)(912.0k)(1.4m)(491.0k)(988.0k)(1.5m)(536.0k)(1.2m)(1.7m)(581.0k)(1.2m)(14.2m)(321.0k)(643.0k)(963.0k)(321.0k)(210.8m)

Cash From Financing Activities

(2.8m)(3.2m)(722.0k)(851.0k)(444.0k)(1.0m)(1.3m)(1.3m)(1.2m)(1.6m)(1.9m)(830.0k)(1.2m)(1.6m)(928.0k)(857.0k)827.0k(1.1m)2.6m2.1m(1.5m)(1.7m)(2.1m)(1.3m)(1.6m)(1.9m)(1.2m)(211.8m)14.3m

Net Change in Cash

(26.9m)(16.7m)(157.3m)(152.5m)(165.5m)3.8m(7.2m)(10.8m)9.0m(9.8m)(10.7m)(95.3m)(127.5m)(75.6m)(178.3m)(164.6m)(164.2m)(44.1m)(15.9m)36.7m(41.2m)(46.6m)(12.8m)(34.6m)(69.3m)89.8m19.5m16.1m(28.6m)

Interest Paid

1.4m1.9m516.0k1.0m1.5m480.0k962.0k1.4m447.0k896.0k1.4m412.0k3.2m3.6m378.0k3.0m3.4m332.0k3.0m3.3m774.0k6.7m10.5m3.7m9.6m13.2m3.7m16.9m

Lexicon Pharmaceuticals Ratios

USDQ2, 2011

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.6 x

Lexicon Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials Products

1

Phase III Trials Products

2

Pre-Clinical Phase Products

1

Products

1

Lexicon Pharmaceuticals Employee Rating

3.540 votes
Culture & Values
4
Work/Life Balance
4
Senior Management
3.1
Salary & Benefits
3.8
Career Opportunities
3.1
Source